BioLineRx gets patent for celiac drug


The USPTO issues a Notice of Allowance to BioLineRx (BLRX) for the composition of BL-7010, a novel polymer for the treatment of celiac disease. The patent, when issued, will be valid until at least 2026.

BL-7010 has a high affinity for gliadins, the immunogenic proteins in gluten that cause celiac disease. By sequestering gliadins, BL-7010 masks them from enzyme degradation and prevents the formation of immunogenic peptides that trigger the immune system. It is excreted with gliadin from the digestive tract and not absorbed by the blood.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs